Yamanoi Takahiko, Shibano Ken, Soeda Tomoko, Hoshi Akihiko, Matsuura Yutaka, Sugiura Yoshihiro, Endo Kazuhiro, Yamamoto Teiji
Department of Neurology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Tohoku J Exp Med. 2004 Jun;203(2):133-9. doi: 10.1620/tjem.203.133.
We report three cases of intracranial aspergillosis originating in the sphenoid sinus in immunocompetent patients. The patients presented with an orbital apex syndrome in that a unilateral loss of vision and cranial nerve III palsy were seen in all cases and a contralateral involvement was also seen in one case. Despite the initial treatment with a conventional dose of itraconazole (ITCZ, 200 mg/day), the neurological deficits failed to improve and the granulomatous inflammation was not suppressed. Therefore, we treated with a combination of a high dose of ITCZ at 500-1000 mg/day (16-24 mg/kg/day) and amphotericin B (AMPH-B) at 0.5 mg/kg/day, in conjunction with a pulse dose of methylprednisolone at 1000 mg/day. Two cases responded favorably in that the ocular movements completely recovered, and their maximum serum concentrations of the hydroxy ITCZ were 7816 ng/ml and 5370 ng/ml. However, the other case worsened, despite ITCZ treatment at 16 mg/kg/day, and the serum concentration of the hydroxy ITCZ was 3863 ng/ml. The surgical decompression of the cavernous sinus via an extradural approach was performed, and the dose of ITCZ was increased to 24 mg/kg/day. The resulting serum concentration of the hydroxy ITCZ was 4753 ng/ml, and the outcome of this case has been favorable. These results suggest that a high blood level of the hydroxy ITCZ (more than 4500 ng/ml) is a prerequisite for the successful treatment of intracranial aspergillosis and that the combination treatment of ITCZ with AMPH-B would be preferred. The concomitant use of steroid and/or surgical decompression should be considered, if the invasiveness is not well-controlled in spite of intensive medical therapy.
我们报告了3例免疫功能正常患者起源于蝶窦的颅内曲霉病。所有患者均表现为眶尖综合征,即均出现单眼视力丧失和动眼神经麻痹,1例还出现对侧受累。尽管最初采用常规剂量的伊曲康唑(ITCZ,200mg/天)治疗,但神经功能缺损未改善,肉芽肿性炎症也未得到抑制。因此,我们采用高剂量ITCZ(500 - 1000mg/天,16 - 24mg/kg/天)与两性霉素B(AMPH - B,0.5mg/kg/天)联合治疗,并联合使用脉冲剂量的甲泼尼龙1000mg/天。2例患者反应良好,眼球运动完全恢复,其羟基伊曲康唑的最大血清浓度分别为7816ng/ml和5370ng/ml。然而,另一例患者尽管接受了16mg/kg/天的ITCZ治疗仍病情恶化,其羟基伊曲康唑的血清浓度为3863ng/ml。通过硬膜外入路对海绵窦进行了手术减压,并将ITCZ剂量增加至24mg/kg/天。由此产生的羟基伊曲康唑血清浓度为4753ng/ml,该病例的结果良好。这些结果表明,高血液水平的羟基伊曲康唑(超过4500ng/ml)是成功治疗颅内曲霉病的先决条件,ITCZ与AMPH - B联合治疗更为可取。如果尽管进行了强化药物治疗侵袭性仍未得到很好控制,则应考虑同时使用类固醇和/或手术减压。